(MENAFN- Ameliorate Digital Consultancy)
As per the study initiated by Evolve Business Intelligence, the global Platelet-Rich Plasma market size accounted for USD 0.624 Billion in 2022, growing at a CAGR of 15.24% from 2023 to 2033. Platelet-rich plasma (PRP) is a regenerative medical treatment derived from a patient's blood. It involves separating and concentrating the platelets from a blood sample, which are then reintroduced into the body at the site of an injury or a medical condition. Platelets contain growth factors and other bioactive proteins that can stimulate tissue repair, reduce inflammation, and promote healing. PRP is used in various medical fields, including orthopedics, sports medicine, dermatology, and dentistry, to accelerate healing and tissue regeneration in conditions like tendon injuries, arthritis, hair loss, and skin rejuvenation. It is considered a minimally invasive and autologous (using the patient's material) therapy with potential benefits in promoting natural healing processes.
The Platelet-Rich Plasma (PRP) market is primarily driven by the growing demand for non-surgical and regenerative medical treatments, particularly in orthopedics and aesthetic medicine, due to their potential to accelerate healing and tissue regeneration. Additionally, increased awareness among patients and healthcare providers about the benefits of PRP therapy contributes to its market growth.
Request Free Sample Report or PDF Copy :
Key Highlights:
The global Platelet-Rich Plasma Market size was valued at USD 0.624 billion in 2022 growing at a CAGR of 15.24% from 2023 to 2033. North America dominated the market in 2022 Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033
Evolve Business Intelligence has recently released a new market research report on the Global Platelet-Rich Plasma Market. The report covers a wide range of aspects, such as market size and forecast, market dynamics, analysis of competitors' market share, value and volume of the market, SWOT analysis, product benchmarking, recent developments of key players, and potential opportunities. Additionally, the market has been assessed based on four indicators in the market dynamic chapter, including Drivers, Restraints, Key Trends, and Challenges.
In terms of COVID-19 impact, the Platelet-Rich Plasma Market report also includes the following data points:
COVID-19 Impact on Platelet-Rich Plasma Market Size End-User/Industry/Application Trend, and Preferences Government Policies/Regulatory Framework Key Players Strategy to Tackle Negative Impact/Post-COVID Strategies Opportunity in the Platelet-Rich Plasma Market
Buy the Latest Copy of the Report Now at Higher Discount:
Key Players
Some of the major Platelet-Rich Plasma market players holding high market shares include Arthrex, Inc., EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, and Terumo Corporation. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders.
The key players profiled in the report are:
Johnson & Johnson Services, Inc Arthrex, Inc EmCyte Corporation PRP USA Juventix Regenerative Medical Terumo Corporation Zimmer Biomet Stryker Apex Biologix Celling Biosciences, Inc
Segmental Analysis
Market Segment By Type with a Focus on market share, consumption trend, and growth rate of the Platelet-Rich Plasma Market:
Pure Platelet Rich Plasma Leukocyte Rich Platelet Plasma Others
Market Segment By Application with a focus on market share, consumption trend, and growth rate of the Platelet-Rich Plasma Market:
Orthopedics Sports Medicine Cosmetic Surgery Dermatology Ophthalmic Surgery Neurosurgery General Surgery Others
Market Segment By End-use with a Focus on market share, consumption trend, and growth rate of the Platelet-Rich Plasma Market:
Parameters | Details |
Market Size (2022) | $ 0.624 Billion |
CAGR (2023 to 2033) | 15.24% |
Market Segmentation | Type, Application, End-use |
Country Covered | US, Canada, Mexico, UK, Germany, France, Italy, Spain, Nordic Countries, BeNeLux, Rest of Europe, China, India, Japan, South Korea, Indonesia, Malaysia, Australia, Rest of Asia Pacific, Middle East & Africa, and South America |
For more information:
Global Platelet-Rich Plasma Market Geographic Coverage:
North America Europe UK Germany France Italy Spain Nordic Countries Benelux Rest of Europe
Asia Pacific China Japan India South Korea Indonesia Malaysia Australia Rest of Asia Pacific
Middle East and Africa Saudi Arabia UAE Egypt South Africa Rest of MEA
Latin America Mexico Brazil Argentina Rest of Latin America
Reasons to Buy this Report:
Detail analysis of the impact of market drivers, restraints, and opportunities Competitive Intelligence provides an understanding of the ecosystem Details analysis of the Total Addressable Market (TAM) of your products Investment Pockets and New Business Opportunities Demand-supply gap analysis Strategy Planning
About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool – EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.
Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email:
Website:
MENAFN22092023004660010643ID1107124274
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.